Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients

Eugen Bellon,Nathaniel Melling,Kai Bachmann,Guido Sauter,Michael Tachezy,Tarik Ghadban,Claudia Hube-Magg,Katharina Grupp,Ronald Simon,Jakob Robert Izbicki

doi:10.1007/s00432-021-03686-4

Abstract

IntroductionLysophosphatidylcholine acyltransferase 1 (LPCAT1) has repeatedly been suggested to be associated with tumorigenesis. To evaluate the role of LPCAT1 in esophageal cancer, LPCAT1 immunostaining was analyzed on a tissue microarray containing samples from esophageal cancer patients.ResultsIn benign esophageal tissue, LPCAT1 staining was detectable in low intensities. LPCAT1 staining was increased in malignant as compared to benign esophageal tissue and was found in high intensity in 26.4% of 288 interpretable esophageal adenocarcinomas (EACs) and in 23.2% of 211 squamous cell carcinomas (ESCCs). Increased LPCAT1 staining was linked to undifferentiated tumor grading in both subtypes of EACs and ESCCs (p = 0.0273 and p = 0.0085).ConclusionHowever, LPCAT1 was not associated with prognosis of EAC and ESCC patients (p = 0.6838 and p = 0.4695) and thus cannot be considered a prognostic biomarker in esophageal cancers.

Highlights

Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has repeatedly been suggested to be associated with tumorigenesis
The results of our study do not support LPCAT1 immunostaining as a prognostic marker in esophageal cancer
High LPCAT1 immunostaining was detectable in 26.4% and 23.2% of the interpretable esophageal adenocarcinomas (EACs) and ESCCs

Summary

Introduction

Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has repeatedly been suggested to be associated with tumorigenesis. Results In benign esophageal tissue, LPCAT1 staining was detectable in low intensities. LPCAT1 staining was increased in malignant as compared to benign esophageal tissue and was found in high intensity in 26.4% of 288 interpretable esophageal adenocarcinomas (EACs) and in 23.2% of 211 squamous cell carcinomas (ESCCs). Conclusion LPCAT1 was not associated with prognosis of EAC and ESCC patients (p = 0.6838 and p = 0.4695) and cannot be considered a prognostic biomarker in esophageal cancers. Dueke et al (1996) showed that the amount of phospholipids in colon cancer tissue is greatly increased and increased synthesis of membrane phospholipids is required for rapid growth during tumor development (Dueke et al 1996). Analyzes from colon cancer cell lines have shown a significant growth advantage when overexpressing LPCAT1

Methods

Results

Conclusion